International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 14s, 2025
https://www.theaspd.com/ijes.php

Modulatory Effects Of Dimethyl Itaconate And CB2 Receptor Activation On BDNF Expression In Paclitaxel Induced Neuroinflammatory Disorders

Amit Kumar Bhatt[1], Krishana Kumar Sharma[2]
[1]Research Scholar, Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Delhi Road, Nh 24, Bagadpur, Moradabad, Uttar Pradesh, 244001, amitsln0330@gmail.com
[2]Professor, Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Delhi Road, Nh 24, Bagadpur, Moradabad, Uttar Pradesh, 244001, krishanas.pharmacy@tmu.ac.in,

Abstract
Brain-Derived Neurotrophic Figure (BDNF) plays a pivotal part in neuroplasticity, neuronal survival, and synaptic balance. however, the dysregulation of this factor, especially its overexpression, is related with different neurological clutters. The Cannabinoid Receptor Type2 (CB2) is perceived as an critical helpful target due to its part in neuroprotection and resistant tweak inside the central apprehensive framework. This study about explores the impacts of CB2 receptor agonists on the overexpression of BDNF using an in vivo demonstrate. Mice gotten treatment with particular CB2 agonists, after which BDNF expression levels were examined utilizing atomic and immunohistochemical strategies. The comes about illustrated that CB2 actuation driven to a diminish in BDNF overexpression, likely through anti-inflammatory instruments and the control of cytokine levels. The comes about recommend that CB2 receptor agonists may serve as potential modulators of BDNF-related neural dysfunctions, advertising a promising restorative pathway for the treatment of neurodegenerative and neuroinflammatory clutters.
Keyword:*CB2 receptor, BDNF, neuroprotection, neuroinflammatory*

INTRODUCTION

The cannabinoid receptor 2 (CB2) possesses seven transmembrane helices, a glycosylated N-terminus, and a cellular matrix-anchored C-terminal helix. For further information, go to the previous section; it has tight ties to the CB1 receptor. The identification of CB2 receptors in 1993 has given us some insight into the immunomodulatory properties of cannabinoids (Munro et al., 1993)[1]. There is a correlation between cannabinoid 2 activation and neuroprotection, bone mass preservation, and inflammation decrease (Mackie, 2008)[2]. Astrocytes, microglia, and immune system cells make up the bulk of CB2-expressing cells in the central nervous system. Dementias and illnesses like Huntington's chorea, which often progress slowly, have been the primary targets of therapeutic research for neurodegenerative diseases (Maccarrone et al., 2007)[3]. The GI/Goa subunits of cannabis receptors decrease adenylyl cyclase activity, as shown by Bouaboula et al. (1996)[4] and Soethoudt et al. (2017)[5]. Interactions with stimulatory Gai/o subunits raise intracellular cAMP levels, which accomplishes the desired effect.

Kelsey, G., Guenther, Xiao-liang, Lin, Zhili, Xu, Alexandros, Makriyannis, Julián, Romero, Cecilia, J., Hillard, Ken, Mackie, Andrea, G., Hohmann. (2024)[9]. In a mouse model of paclitaxel-induced neuropathic nociception, the research showed that CB2 agonists' anti-allodynic effects were dependent on CB2 receptors in primary sensory neurons. Additionally, the study indicated that paclitaxel-treated female mice did not exhibit a sexually dimorphic sparing of morphine tolerance in response to cannabinoid agonists acting on primary sensory neurons.Vittoria, Borgonetti, Claudia, Mugnaini, Federico, Corelli, Nicoletta, Galeotti. (2023)[10]. In a preclinical model of peripheral neuropathy known as the sparing nerve injury (SNI), the purpose of the study was to investigate the anti-neuropathic effect of a new selective CB2 agonist known as COR167. After acute and repeated treatment, oral COR167 was able to reduce mechanical allodynia and thermal

hyperalgesia in a dose-dependent manner, demonstrating that tolerance induction was not induced. There was no discernible change in locomotor behavior when COR167 was administered at levels that were anti-neuropathic. In addition to NF-kB activation, SNI animals exhibited elevated levels of HDAC1 protein in the microglia located on the ipsilateral side of the spinal cord. Through a process that is mediated by CB2, the treatment with COR167 was able to inhibit the overexpression of HDAC1 and the activation of NF-kB, while simultaneously increasing the levels of the anti-inflammatory cytokine IL-10. When it comes to the treatment of neuropathic pain problems, the administration of COR167 by oral administration shown remarkable therapeutic potential.

Bergen M. et al. (2020)11 investigated the relationship between cannabis, endocannabinoids, and brain-derived neurotrophic calculate within the setting of "neurogenic and neuroplastic brain processes." Over the course of a person's lifetime, the brain continues to be the foremost complex organ within the mammalian body. It has a surprising potential for versatility and improvement, contributing to its astounding capacity for alter. interior the scope of this ponder, the interaction between endocannabinoids (eCB) and brain-derived neurotrophic calculate (BDNF) is explored in connection to a wide assortment of morphological, neurodevelopmental, and anatomical processes that happen interior the brain. Cross-talk between eCB and BDNF may be a bidirectional energetic prepare that's exceptionally complicated. It is mindful for advancing neuronal multiplication, separation, spatial advancement, neural connection arrangement, and "modified cell passing occasions" in both embryonic and grown-up neurogenesis. The coupled activity of BDNF and eCBsignalling, which capacities as a utilitarian controller of neuroplasticity, is mindful for balancing the quality of synaptic motivations between excitatory and inhibitory neurons. "This controls the "neurobiology of memory and learning," which controls forms such as "long-term" discouragement and "long-term" potentiation".

Burston, J. J., et al. (2013)12 "Cannabinoid CB2 receptor actuation diminishes central and fringe neuropathic torment." In this think about, we appear that cannabinoid receptor agonists are compelling analgesics in creature models of neuropathy. It appears considerable diminishes in hyperalgesia and allodynia and gives a exhaustive examination of the central and fringe forms behind CB2-mediated torment lightening. Whereas cannabinoids at CB1 receptors are known to supply inebriating impacts, the creators stretch that enactment of CB2 receptors is pivotal in lessening neuroinflammation. These comes about have critical suggestions for the potential synergistic anti-inflammatory impacts of CB2 agonists and Dimethyl itaconate. The comes about of this inquire about give unused data on cannabinoid-targeted medicines for neuropathic torment, which may one day replace opioids.

Zhang, Y., et al. (2020)13 "The part of Cannabinoid Receptor 2 in neuropathic torment administration." Investigate into the adequacy of enacting CB2 receptors within the treatment of neuropathic torment is the center of this examination. This finding loans assurance to the thought that CB2-mediated pathways involvement less aggravation, oxidative harm, and torment practices. The synergistic impacts of CB2 agonists and anti-inflammatory drugs like Dimethyl itaconate are moreover explored in this think about. Enhancing cannabinoid-based therapeutics for neuropathy may be superior caught on by concentrating on preclinical models, which are the subject of this inquire about. This asset is basic for analysts within the field of torment pharmacology, since the comes about bolster the helpful rationale of focusing on CB2 receptors in complicated torment clutters. Huang, W. J., et al. (2022)14 "Developing atomic targets for neuropathic torment treatment." The center of this investigate is on cannabinoid 2 receptors (CB2 receptors) and anti-inflammatory drugs such as dimethyl itaconate as potential modern pharmaceutical targets for neuropathic torment. Atomic forms and treatment viability in preclinical models are nitty gritty within the authors' careful evaluation of current progresses in sedate improvement. In handling neuroinflammatory torment pathways, they accentuate how cancer prevention agents and CB2 receptor agonists work together. For way better help from neuropathic torment, this review may be utilized as a guide to make multimodal medications that combine intercessions based on cannabinoids with modern anti-inflammatory approaches.

Finnerup, N. B., et al. (2015)15 "Pharmacotherapy for neuropathic torment in grown-ups: A efficient survey." Pharmacological medications for neuropathic torment, counting non-opioid solutions such CB2 receptor agonists, are assessed in this comprehensive audit. It digs into the benefits they give over conventional treatments by talking about the prove that they work in both clinical and preclinical contexts. To encourage progress anti-inflammatory and antioxidant comes about, the investigation digs into the utilize of aide medications such as dimethyl itaconate. This think about traces potential future investigate bearings and gives a bird's-eye see of the show state of neuropathic torment treatment. Wang, L., et al. (2021)16 "Oxidative stretch and neuroinflammation in cisplatin-induced neuropathic torment." The relationship between oxidative push, neuroinflammation, and cisplatin-induced neuropathic torment is investigated in this inquire about. It underscores the plausibility that Dimethyl itaconate, through its NRF2-mediated antioxidant pathways, might diminish these impacts. The comes about appear that Dimethyl itaconate may decrease aggravation and torment practices in cisplatin mice, loaning assurance to its utilize as a neuroprotective medicate. In arrange to lighten chemotherapy-induced neuropathy, this think about highlights the importance of oxidative stretch focusing on and lays the basis for future ponders on combination medicines utilizing CB2 agonists and Dimethyl itaconate. Jain, K., Barve, K., & Bhatt, L. K. (2022)17 "Gasdermins: Pore-forming Proteins as a Potential Restorative Target." Neuropathy brought on by cisplatin-induced harm is the most center of this investigate, which points to look at the administrative capabilities of Dimethyl itaconate in adjusting the immunological reaction. Its conceivable cooperative energy with CB2 receptor agonists is proposed by the creators, who too note its work in directing incendiary pathways. The potential anti-oxidative impacts of dimethyl itaconate on oxidative stress caused by chemotherapy are moreover talked about. Inquire about highlights its potential as a treatment for neuropathy and suggests unused ways to progress comes about by combining it with CB2 receptor agonists. We get distant a much better get a handle on of non-opioid treatment approaches for neuropathic disarranges from this ponder.

Crystal Structure of CB2

The first crystal structure of CB2, complexed with the high-affinity synthetic antagonist AM10257, was documented by Hua and colleagues in 2019 (PDB:5ZTY, Figure 3, Video S2) (Li et al., 2019)[6].The C-terminal intracellular helix assumes an inactive conformation similar to that of antagonist-bound CB1; the extracellular regions of antagonist-bound CB2 and CB1 exhibit notable differences, particularly in TM1 and TM2. In contrast to its use of a V-shaped



Figure 1. Analysing the Differences Between the Ligand-Binding Modes of CB1 and CB2

Both A and B The blue ligand-binding pockets of AM6538CB1 (5TGZ) and AM10257CB2 (5ZTY) are visible in (A), whereas the orange and orange conformational differences of F200 and W258 in antagonist-bound CB2 and CB1 are shown in (B). We look at AM12033CB2 (6KPC), an agonist for gold, and AM10257CB2, an agonist for orange, and compare and contrast their "toggle switch" residue structures (5ZTY, AM10257). From position D to position G, the orthosteric pocket of AM10257CB2 is orange, whereas the ligand's direct interaction with residues F1173.36 and W2586.48 is shown by the yellow of WIN55212-2CB2 (6PT0). At the

macroscopic level, we can see that certain receptors are active (receptor E) while others are inert (receptor F) and G). At AM10257CB2, the N-terminal helix is located on top of the orthosteric pocket, however unlike at antagonised CB1, it does not directly engage in antagonist binding. However, just like with CB1, an internal disulphide bond (C174-C179) strengthens ECL2 in CB2. The fundamental conformational lock is maintained by this bond, which keeps the binding site in the ligand-binding conformation.

In preparation for this study, Hua and colleagues published the crystal structure of the AM12033 agonist complexed with CB2, which is shown in Figure 3, Video S2. Thanks to X-ray diffraction data, this structure was created and assigned the PDB number 6KPC.The authors Hua et al. (2020)[7]. The majority of the interactions between AM12033CB2 are aromatic or hydrophobic, as seen in Table 1. The binding pockets of AM12033, an agonist, and AM10257, an antagonist, were quite comparable. However, because the extracellular parts of TM1, TM4, and TM7 were pushed inward, the agonist adhered to a somewhat smaller binding pocket. According to 2020 study by Hua et al., the "toggle switch" of W2586.48 changes drastically in AM12033CB2 (Figure 5C).

The electron microscopy structure of CB2 complexed with the stronger agonist WIN55,212-2 was recorded by Xing et al. (2020)[8] (Figure 3; PDB: 6PT0, Video S2). They worked separately to complete the research as well. The AM12033 CB2 and this structure are quite similar, however there are a few important distinctions: Compared to WIN55,212-2, AM10257 may bind to the binding pocket of the W2586.48 toggle switch more deeply (about 2.8 Å), resulting in the creation of different conformations. The little rotation of F1173.36, which permits it to bind with WIN 55,212-2 in a minimal manner, causes W2586.48 to be 1.2 Å further from the ligand than AM10257, as seen in Figure 5D. The next step is to move the cytoplasmic end of TM6 outside the cell, which further enlarges the G protein binding site. The amount of agonism exerted by CB2 ligands is sensitive to even minute changes caused by steric effects on W2586.48 (Figure 5D).

There are some similarities between AM841CB1 and AM12033CB2, but their activation mechanisms and the procedures that govern the selection of ligands and G proteins are different (Figures 5E-5G). The variation in cannabinoid receptor G protein coupling may be affected by the one residue difference in ICL-2, which is P139 in CB2 and L222 in CB1. To activate adenylate cyclase and phospholipase C, as well as increase cytosolic Ca2+ levels, CB1 can interact with other G proteins, even though CB2 is a monomer of G proteins. The structural similarity between the orthosteric binding sites of CB2 and CB1, which are bound by agonists, is a big hurdle in the creation of receptor-selective agonists.

OBJECTIVE OF THE STUDY

1. Investigate the role of CB2 activation in regulating BDNF expression levels.
2. To examine the effect of CB2 agonists on BDNF expression.

METHODOLOGY

This research employed adult male mice weighing between 20 and 25 grams. The environment was carefully controlled to maintain a temperature of 22 ± 2°c, with a 12-hour cycle of light and darkness. The animals were given a consistent pellet diet and unrestricted access to water throughout the duration of the experiment. All animal-handling procedures were thoroughly examined and approved by the committee for the purpose of control and supervision of experiments on animals (cpcsea) and carried out with utmost compliance to the guidelines established by the committee for control and supervision of experiments on animals (ccsea).

The scientists caused neuropathic pain by injecting paclitaxel (pt) into the mice veins at a dose of 2 mg per kilogram of body weight every day for five days. The progress and improvement in neuropathic pain were evaluated by measuring pain thresholds on days 0, 4, 8, 12, and 16 after the treatment.

The drug paclitaxel was obtained from Sigma Chemical Company and prepared as a fresh suspension in sterile saline before administration. Dimethyl itaconate (DI), which was produced by j.s.p enterprise, was synthesized for the first time before being utilized in each experiment. Dimethyl itaconate (DI) was administered through an intraperitoneal injection at levels determined by previous studies and initial trials.

The administration of medication commenced once the healthcare provider confirmed the patient's discomfort.

The animals were randomly assigned to six experimental groups. Group i served as the control group and did not receive any intervention or therapy. Group II was administered intraperitoneal di at a dosage of 400 mg/kg, starting on day 6 and continuing for 10 days. Group III was administered paclitaxel (2 mg/kg, intravenously) for a period of five days. Groups iv and v were administered with dosages of 200 mg/kg and 400 mg/kg, respectively, through intraperitoneal injections starting on day 6 and continuing for a period of 10 days. In both groups, the pt received a 10-minute break after the injection. Group vi was administered pregabalin at a dosage of 5 mg/kg via intraperitoneal injection, starting on day 6 and continuing for a period of 10 days as the standard treatment.

Behavioral testwere employed to measure the advancement and effectiveness of interventions for neuropathic pain. Thermal hyperalgesia was examined by a hot plate or plantar test, whilst mechanical allodynia was measured using von frey filaments. All behavioural assessments were conducted in a controlled setting, with the evaluator blinded to group allocations to mitigate bias.

Upon completion of the behavioural experiments, the animals were euthanised, and organs such as the dorsal root ganglia, spinal cord, and hind paw were harvested for biochemical analysis. Inflammatory cytokines, including interleukin-1 (il-1), tumour necrosis factor-alpha (tnf-α), and interleukin-6 (il-6), were measured using enzyme-linked immunosorbent assay (elisa) kits to evaluate the degree of neuroinflammation and the anti-inflammatory efficacy of the therapies.

Data were presented as mean ± standard deviation. Statistical significance was assessed using one-way or two-way analysis of variance (ANOVA), test. A probability below 0.05 was deemed statistically significant.

Statistical analysis

1. Assessment ofPaw Heat-Hyperalgesia (Hot Plate Method)



Figure 2. Hot Plate Test (Withdrawal Latency in Seconds)

TABLE 1: Hot Plate Test

Hot Plate Method -		Withdrawal Latency in Seconds					
		DAYS					
			0	4	8	12	16
Group I Uninduced Untreated Control	Untreated Uninduced	1	6	6	5	5	5
		2	5	5	5	5	6
		3	6	6	5	6	6
		4	5	6	6	6	4
		5	6	5	6	4	5
		6	6	6	4	4	5
		Avg	5.67	5.33	5.17	5.17	5.17
		Stdev	0.52	0.82	0.75	0.75	0.75
Group II DI 400mpk	Treated Uninduced	1	8	8	8	8	8
		2	8	9	8	8	8
		3	9	8	9	7	7
		4	7	7	7	9	8
		5	6	5	6	4	5
		6	8	8	8	6	8
		Avg	8.00	7.83	8.00	7.50	8.00
		Stdev	0.63	0.75	0.63	1.05	0.63
Group III PT 2mpk	Induced Untreated	1	2	3	1	3	3
		2	1	1	1	3	2
		3	1	1	3	2	2
		4	2	2	2	1	3
		5	1	2	2	2	1
		6	2	1	3	2	1
		Avg	1.50	1.67	2.00	2.17	2.00
		Stdev	0.55	0.82	0.89	0.75	0.89
Group IV 200mpk DI	DI 200 MPK	1	3	4	3	4	3
		2	3	4	4	3	5
		3	4	3	4	5	4
		4	4	2	3	4	4
		5	3	3	2	5	3
		6	2	3	2	4	2
		Avg	3.17	3.17	3.00	4.17	3.50
		Stdev	0.75	0.75	0.89	0.75	1.05
Group V 400MPK DI	DI 400 MPK	1	5	5	5	5	7
		2	5	7	5	6	5
		3	6	6	7	6	6
		4	6	6	5	7	6
		5	5	5	6	5	7
		6	7	6	5	6	5
		Avg	5.67	5.83	5.50	5.83	6.00
		Stdev	0.82	0.75	0.84	0.75	0.89
Group VI PREG 5 MPK	Pregabalin 5 MPK	1	5	8	5	5	8
		2	6	8	6	5	5

		3	6	7	6	6	6
		4	5	5	7	7	5
		5	6	6	8	5	8
		6	7	6	8	8	7
		Avg	5.83	6.67	6.67	6.00	6.50
		Stdev	0.75	1.21	1.21	1.26	1.38

Anova: Single Factor				
SUMMARY				
Groups	*Count*	*Sum*	*Average*	*Variance*
Group I Untreated Uninduced	5	26.51	5.302	0.04712
Group II Treated Uninduced	5	39.33	7.866	0.04728
Group III PT 2mpk	5	9.34	1.868	0.07517
Group IV 200mpk DI	5	17.01	3.402	0.21717
Group V 400MPK DI	5	28.83	5.766	0.03573
Group VI PREG 5 MPK	5	31.67	6.334	0.15473

ANOVA						
Source of Variation	*SS*	*df*	*MS*	*F*	*P-value*	*F crit*
Between Groups	114.9313	5	22.98626	238.9424	1.2E-19	2.620654
Within Groups	2.3088	24	0.0962			
Total	117.2401	29				

The Hot Plate Strategy measures withdrawal idleness to assess torment affectability over diverse treatment groups over 16 days.

In Group I (Untreated Uninduced), the normal withdrawal idleness remained generally steady, extending from 5.17 to 5.67 seconds all through the think about. The standard deviation changed between 0.52 and 0.82, showing direct consistency. This recommends that without any treatment or initiated condition, torment affectability remained steady with no noteworthy change over time.

Group II (Treated Uninduced) displayed higher withdrawal latencies, beginning at 8.00 seconds on Day and keeping up comparable values all through the consider, with minor vacillations. The normal inactivity extended from 7.50 to 8.00 seconds, and the standard deviation remained moo (0.63 to 1.05), recommending reliable torment resilience. This shows that the treatment viably kept up torment resistance without noteworthy changes over time.

In Gather III (Actuated Untreated), the withdrawal idleness was altogether lower than other groups, beginning at 1.50 seconds on Day and fluctuating somewhat to 2.17 seconds on Day 12 some time recently settling at 2.00 seconds on Day 16. The standard deviation changed between 0.55 and 0.89, reflecting moo but steady torment resilience. These comes about recommend that the initiated condition expanded torment affectability, and without treatment, no significant recuperation occurred.

Group IV (DI 200 MPK) appeared slight change in withdrawal inactivity over time. The normal expanded from 3.17 seconds on Day to 4.17 seconds on Day 12, with a slight decrease to 3.50 seconds on Day 16. The standard deviation extended from 0.75 to 1.05, reflecting direct changeability. This shows that DI 200 MPK treatment given gentle torment help, especially by Day 12, in spite of the fact that its impact was not reliably progressive.

Group V (DI 400 MPK) shown higher withdrawal latencies than the lower measurements gather. Beginning at 5.67 seconds, the normal expanded to 6.00 seconds by Day 16, showing maintained torment resistance. The standard deviation extended from 0.75 to 0.89, reflecting steady reactions. This recommends that DI 400 MPK treatment advertised more reliable torment help compared to the lower dose.
Group VI (Pregabalin 5 MPK) appeared moved forward withdrawal latencies, starting at 5.83 seconds on Day and expanding to 6.50 seconds by Day 16. The standard deviation extended from 0.75 to 1.38, appearing marginally higher changeability. This recommends that Pregabalin 5 MPK given compelling torment help, which was maintained and somewhat upgraded over time.
In conclusion, Gather III (Initiated Untreated) appeared the most noteworthy torment affectability, whereas Bunch II (Treated Uninduced) and Bunch V (DI 400 MPK) displayed the foremost steady torment help. The DI 400 MPK and Pregabalin 5 MPK medicines were the foremost compelling in upgrading pain tolerance over the perception period.

2.Assessment of Thermal hyperalgesia(Plantar Test)



Figure 3. Plantar Test (Withdrawal Latency in Seconds)

TABLE 2: Plantar Test

Plantar Test		Withdrawal Latency in Seconds					
		Days					
			0	4	8	12	16
Group I Uninduced Untreated Control	Untreated Uninduced	1	12	13	13	12	12
		2	13	12	13	14	14
		3	11	12	13	13	11
		4	11	11	14	12	13
		5	11	13	12	13	12
		6	12	12	12	13	12
		Avg	11.83	12.17	12.83	12.5	12.33
		Stdev	0.75	0.75	0.75	1.05	1.03

Group II DI 400mpk	Treated Uninduced	1	17	15	16	15	16
		2	16	16	15	15	16
		3	14	16	15	16	17
		4	15	15	15	16	15
		5	17	17	17	15	15
		6	17	15	16	17	16
		Avg	16	15.67	15.67	15.67	15.83
Group III PT 2mpk		Stdev	1.26	0.82	0.82	0.82	0.75
	Induced Untreated	1	6	8	8	8	6
		2	8	7	7	8	8
		3	8	6	7	7	8
		4	7	7	8	6	7
		5	8	6	6	7	8
		6	8	6	7	8	8
		Avg	7.5	6.67	7.17	7.33	7.5
		Stdev	0.84	0.82	0.75	0.82	0.84
Group IV 200mpk DI	DI 200 MPK	1	10	7	10	8	10
		2	8	8	10	8	10
		3	8	8	11	7	8
		4	10	8	8	10	7
		5	7	7	7	10	8
		6	7	10	8	8	8
		Avg	8.33	8	9	8.5	8.5
		Stdev	1.37	1.1	1.22	1.22	1.22
Group V 400MPK DI	DI 400 MPK	1	10	12	10	10	12
		2	11	10	12	12	10
		3	11	12	12	12	11
		4	10	12	11	11	12
		5	9	11	12	12	10
		6	12	12	10	12	12
		Avg	10.5	11.5	11.17	11.5	11.17
		Stdev	1.05	0.84	0.98	0.84	0.98

Group VI PREG 5 MPK Stdev	Pregabalin 5 MPK	1	12	14	13	13	13
		2	12	13	14	14	13
		3	13	13	14	14	13
		4	14	14	14	12	12
		5	14	13	12	14	14
		6	13	12	13	13	14
		Avg	14	13.17	13.33	13	13.17
		Stdev	0.89	0.75	0.82	0.89	0.75

Anova: Single Factor

SUMMARY

Groups	*Count*	*Sum*	*Average*	*Variance*
Group I Untreated Uninduced	5	61.66	12.332	0.13862
Group II Treated Uninduced	5	78.84	15.768	0.02162
Group III PT 2mpk	5	36.17	7.234	0.11823
Group IV 200mpk DI	5	42.33	8.466	0.13078
Group V 400MPK DI	5	55.84	11.168	0.16667
Group VI PREG 5 MPK	5	66.67	13.334	0.15223

ANOVA						
Source of Variation	*SS*	*df*	MS	*F*	*Pvalue*	*F crit*
Between Groups	248.5227	5	49.70454	409.5684	2.08E-22	2.620654
Within Groups	2.9126	24	0.121358			
Total	251.4353	29				

The plantar test measures withdrawal idleness in seconds, reflecting the torment edge and the pain relieving impacts of distinctive medicines. The comes about uncover clear varieties over bunches and time focuses (Day to Day 16).

Group I (Untreated Uninduced) kept up a generally steady withdrawal idleness, with midpoints extending from 11.83 to 12.83 seconds. This shows a reliable torment edge without any outside treatment, as reflected by the moo standard deviation (0.75-1.05), implying negligible variety between subjects.

Group II (Treated Uninduced) appeared the next and reliable withdrawal inactivity compared to the untreated uninduced gather, extending from 15.67 to 16.00 seconds. This proposes that the treatment essentially expanded torment resistance in uninduced subjects. The standard deviation (0.75-1.26) shows slight inconstancy among subjects but does not weaken the slant of expanded latency.

Group III (Actuated Untreated) recorded the least withdrawal latencies over all time focuses, with midpoints extending from 6.67 to 7.50 seconds. This proposes that acceptance brings down the torment limit, making subjects more touchy to jolts. The moo standard deviation (0.75-0.84) reflects reliable torment affectability among subjects in this group.

Group IV (DI 200 MPK) illustrated a direct increment in withdrawal inactivity compared to the initiated untreated bunch, with midpoints between 8.00 and 9.00 seconds. This shows a fractional pain relieving impact, in spite of the fact that it is less articulated than in bunches accepting higher dosages. The standard deviation (1.10-1.37) reflects marginally more prominent inconstancy, proposing contrasts in person reactions to the treatment.

Group V (DI 400 MPK) shown higher withdrawal latencies than the actuated untreated and DI 200 MPK bunches, with midpoints extending from 10.50 to 11.50 seconds. This demonstrates a more grounded pain relieving impact at the higher measurements, in spite of the fact that it did not reach the levels seen within the treated uninduced bunch. The standard deviation (0.84-1.05) demonstrates minor inconstancy in reaction to the treatment.

Group VI (Pregabalin 5 MPK) shown the most elevated withdrawal latencies among all actuated bunches, extending from 13.00 to 14.00 seconds. This proposes that pregabalin gives a critical and supported pain relieving impact. The moo standard deviation (0.75-0.89) shows reliable reactions among subjects, strengthening the adequacy of pregabalin in upgrading torment tolerance.

Overall, the comes about demonstrate that acceptance essentially brings down torment limits, whereas medicines increment torment resilience to shifting degrees. DI 400 MPK and pregabalin illustrate considerable pain-relieving impacts, with pregabalin giving the foremost steady and maintained torment alleviation. Inconstancy in reactions over bunches is for the most part moo, guaranteeing the unwavering quality of the watched trends.

3.Assessment of TNF-alpha Levels



Figure 4. TNF (Serum) OD450



TNF-alpha ELISA

TABLE 3 : TNF (OD450)

TNF

OD 450

Days							
			0	4	8	12	16
Group I Uninduced Untreated Control	Untreated Uninduced	1	0.02	0.05	0.06	0.06	0.05
		2	0.04	0.05	0.05	0.05	0.05
		3	0.04	0.04	0.05	0.05	0.05
		4	0.05	0.04	0.05	0.04	0.04
		5	0.06	0.05	0.04	0.04	0.04
		6	0.04	0.05	0.04	0.05	0.04
		Avg	0.04	0.05	0.05	0.05	0.05
		Stdev	0.01	0.01	0.01	0.01	0.01
Group II DI 400mpk	Treated Uninduced	1	0.05	0.04	0.05	0.04	0.06
		2	0.05	0.04	0.05	0.05	0.05
		3	0.05	0.06	0.04	0.05	0.04
		4	0.04	0.04	0.04	0.06	0.04
		5	0.04	0.04	0.06	0.04	0.05
		6	0.06	0.05	0.05	0.05	0.04
		Avg	0.05	0.05	0.05	0.05	0.05
		Stdev	0.01	0.01	0.01	0.01	0.01
Group III PT 2rnpk	Induced Untreated	1	1.68	1.48	1.49	1.51	1.62
		2	1.65	1.59	1.57	1.54	1.53
		3	1.58	1.54	1.49	1.49	1.44
		4	1.62	1.62	1.53	1.58	1.41
		5	1.58	1.54	1.35	1.54	1.61
		6	1.47	1.42	1.66	1.61	1.49
		Avg	1.6	1.53	1.52	1.55	1.52
		Stdev	0.07	0.07	0.1	0.04	0.09
	DI 200 MPK	1	1.43	1.26	1.34	1.44	1.35
		2	1.32	1.25	1.36	1.48	1.41
		3	1.36	1.34	1.38	1.35	1.26
		4	1.41	1.54	1.43	1.46	1.41

Group IV 200mpk DI		5	1.46	1.42	1.47	1.55	1.38
		6	1.37	1.49	1.32	1.41	1.35
		Avg	1.39	1.38	1.38	1.45	1.36
		Stdev	0.05	0.12	0.06	0.07	0.06
	DI 400 MPK	1	1.26	1.28	1.16	1.06	1.06
		2	1.24	1.26	1.17	1.05	1.18
		3	1.28	1.24	1.06	1.16	1.15
		4	1.15	1.05	1.19	1.03	1.04
Group V 400MPK DI		5	1.16	1.11	1.03	0.14	1.28
		6	1.14	1.09	1.17	1.19	1.17
		Avg	1.21	1.17	1.13	0.94	1.15
		Stdev	0.06	0.1	0.07	0.4	0.09
	PREGABALIN 5 MPK	1	0.95	0.74	1.08	1.15	1.15
		2	0.91	0.76	1.15	1.06	1.11
		3	1.06	1.13	1.07	1.15	1.09
Group VI PREG 5 MPK		4	1.24	0.95	1.15	1.11	0.82
		5	0.81	0.95	1.27	1.08	0.73
		6	0.72	1.03	1.03	1.14	0.78
		Avg	0.95	0.93	1.13	1.12	0.95
		Stdev	0.18	0.15	0.09	0.04	0.19

Anova: Single Factor				
SUMMARY				
Groups	*Count*	*Sum*	*Average*	*Variance*
Group I Untreated Uninduced	5	0.24	0.048	0.00002
Group II Treated Uninduced	5	0.25	0.05	0
Group III PT 2mpk	5	7.72	1.544	0.00113
Group IV 200mpk DI	5	6.96	1.392	0.00117
Group V 400MPK DI	5	5.6	1.12	0.011
Group VI PREG 5 MPK	5	5.09	1.018	0.00957

ANOVA						
Source of Variation	*SS*	*df*	MS	*F*	*P-value*	*F crit*
Between Groups	10.79432	5	2.158864	565.8883	4.49E-24	2.620654
Within Groups	0.09156	24	0.003815			
Total	10.88588	29				

The TNF (tumor necrosis factor) investigation reflects cytokine movement related with provocative forms. The untreated uninduced bunch appears reliably OD450 values, proposing negligible TNF generation. So also, the treated uninduced gather keeps up moo levels, showing that the treatment does not lift TNF. In contrast, the initiated untreated gather shows a critical increment in OD450, reflecting raised TNF levels and an dynamic provocative reaction. Both DI 200 MPK and DI 400 MPK groups appear diminished TNF levels compared to the actuated untreated gather, demonstrating the anti-inflammatory adequacy of these medications. The Pregabalin 5 MPK bunch too illustrates lower TNF levels, supporting its viability in diminishing aggravation. Standard deviations stay little over all groups, recommending solid and reproducible information. This examination proposes that DI and Pregabalin medications altogether smother TNF generation, lessening fiery action in a dose-dependent way.

4. Assessment of IL-1 Levels



Figure 5. IL-1(Serum) OD450

IL-1 ELISA

TABLE 4: IL-1 (OD450)

IL1	OD450						
Days							
			0	4	8	12	16
Group I Uninduced Untreated Control	Untreated Uninduced	1	0.08	0.07	0.07	0.08	0.09
		2	0.07	0.07	0.07	0.08	0.08
		3	0.07	0.08	0.08	0.07	0.08
		4	0.07	0.08	0.08	0.07	0.07
		5	0.09	0.09	0.07	0.08	0.08
		6	0.07	0.07	0.07	0.09	0.08
		Avg	0.08	0.08	0.07	0.08	0.08
		Stdev	0.01	0.01	0.01	0.01	0.01
Group II DI 400mpk	Treated Uninduced	1	0.08	0.08	0.07	0.08	0.09
		2	0.08	0.08	0.07	0.08	0.09
		3	0.08	0.07	0.08	0.08	0.08
		4	0.07	0.08	0.08	0.07	0.07
		5	0.09	0.09	0.07	0.09	0.07
		6	0.07	0.07	0.07	0.09	0.07
		Avg	0.08	0.08	0.07	0.08	0.08
		Stdev	0.01	0.01	0.01	0.01	0.01
Group III PT 2mpk	Induced Untreated	1	1.13	2.14	2.15	2.19	2.14
		2	2.17	2.15	2.18	2.17	2.16
		3	2.11	2.18	2.16	2.15	2.15
		4	2.15	2.16	2.14	1.15	2.17
		5	2.15	2.16	2.17	1.19	2.16
		6	2.11	2.14	2.16	2.16	2.18
		Avg	1.97	2.16	2.16	1.84	2.16
		Stdev	0.41	0.02	0.01	0.52	0.01
Group IV 200mpk DI	DI 200 MPK	1	2.14	2.16	2.06	2.15	2.15
		2	2.14	2.16	2.15	2.21	2.15
		3	2.15	2.24	2.17	1.95	2.18
		4	2.19	1.17	1.13	2.16	1.06
		5	2.18	2.11	2.17	2.16	2.13
		6	2.17	2.09	2.16	1.08	2.17
		Avg	2.16	1.99	1.97	1.95	1.97

		Stdev	0.02	0.40	0.42	0.44	0.45
Group V 400MPK DI	DI 400 MPK	1	0.85	0.75	0.85	0.73	0.69
		2	0.84	0.81	0.73	0.82	0.84
		3	0.79	0.93	0.75	0.84	0.76
		4	0.92	0.74	0.96	0.96	0.94
		5	0.73	0.81	0.71	0.97	0.83
		6	0.82	0.92	0.73	0.71	0.72
		Avg	0.83	0.83	0.79	0.84	0.80
		Stdev	0.06	0.08	0.10	0.11	0.09
Group VI PREG 5 MPK	PREGABALIN 5 MPK	1	0.53	0.68	0.43	0.51	0.67
		2	0.51	0.59	0.48	0.43	0.64
		3	0.46	0.54	0.64	0.36	0.53
		4	0.68	0.55	0.71	0.58	0.43
		5	0.64	0.42	0.63	0.42	0.47
		6	0.68	0.49	0.51	0.39	0.38
		Avg	0.58	0.55	0.57	0.45	0.52
		Stdev	0.10	0.09	0.11	0.08	0.12

Anova: Single Factor				
SUMMARY				
Groups	*Count*	*Sum*	*Average*	*Variance*
Group I Untreated Uninduced	5	0.39	0.078	0.00002
Group II Treated Uninduced	5	0.4	0.08	5E-05
Group III PT 2mpk	5	10.29	2.058	0.02162
Group IV 200mpk DI	5	10.04	2.008	0.00742
Group V 400MPK DI	5	4.09	0.818	0.00047
Group VI PREG 5 MPK	5	2.67	0.534	0.00273

ANOVA						
Source of Variation	*SS*	*df*	*MS*	*F*	*P-value*	*F crit*
Between Groups	20.26115	5	4.052229	752.5031	1.51E-25	2.620654
Within Groups	0.12924	24	0.005385			
Total	20.39039	29				

The IL-1 investigation assesses safe enactment through interleukin-2 levels over different groups. The untreated uninduced and treated uninduced groups keep up steady OD450 values, showing negligible resistant actuation. The actuated untreated gather appears a stamped increment in IL-1 levels, reflecting improved resistant framework incitement. DI 200 MPK and DI 400 MPK medications decrease IL-1 levels compared to the initiated untreated bunch, proposing an immunomodulatory impact. Among these, the DI

400 MPK bunch appears the most noteworthy concealment of IL-1, demonstrating more grounded adequacy. The Pregabalin 5 MPK gather shows direct IL-1 levels, recommending it too tweaks safe movement. Standard deviations are generally reliable, supporting the unwavering quality of the discoveries. This informationproposes that higher dosages of DI successfully decrease resistant enactment, whereas Pregabalin shows a direct suppressive impact on IL-1 production.

5. Assessment of IL-6 Levels



Figure 6. IL-6 (Serum) OD450

IL6



IL-6 ELISA

TABLE 5 : IL-6 (OD450)

IL6	OD450						
	Days						
			0	4	8	12	16
Group I Uninduced Untreated Control	Untreated Uninduced	1	0.05	0.06	0.05	0.05	0.06
		2	0.06	0.05	0.06	0.06	0.05
		3	0.05	0.06	0.06	0.05	0.04
		4	0.04	0.04	0.05	0.06	0.05
		5	0.05	0.04	0.04	0.04	0.05
		6	0.06	0.05	0.04	0.05	0.06
		Avg	0.05	0.05	0.05	0.05	0.05
		Stdev	0.01	0.01	0.01	0.01	0.01
Group II DI 400mpk	Treated Uninduced	1	0.06	0.06	0.06	0.06	0.05
		2	0.05	0.05	0.05	0.05	0.04
		3	0.05	0.05	0.04	0.04	0.06
		4	0.04	0.06	0.04	0.06	0.04
		5	0.05	0.05	0.04	0.05	0.05
		6	0.06	0.05	0.04	0.04	0.06
		Avg	0.05	0.05	0.05	0.05	0.05
		Stdev	0.01	0.01	0.01	0.01	0.01
Group III PT 2mpk	Induced Untreated	1	2.15	2.08	1.95	2.18	2.16
		2	2.16	2.19	1.98	1.24	2.27
		3	2.15	2.15	2.05	2.27	2.14
		4	1.98	2.24	2.14	2.16	2.16
		5	2.05	2.26	2.16	2.29	2.18
		6	2.17	2.17	2.14	2.11	2.21
		Avg	2.11	2.18	2.07	2.04	2.19
		Stdev	0.08	0.06	0.09	0.4	0.05
	DI 200 MPK	1	1.85	1.74	1.72	1.72	1.73
		2	1.76	1.73	1.69	1.84	1.73
		3	1.95	1.83	1.84	1.83	1.84
		4	1.84	1.76	1.82	1.74	1.72

Group IV 200mpk DI		5	1.82	1.95	1.96	1.73	1.77
		6	1.73	1.84	1.71	1.74	1.82
		Avg	1.83	1.81	1.79	1.77	1.77
		Stdev	0.08	0.08	0.1	0.05	0.05
	DI 400 MPK	1	1.43	1.46	1.32	1.46	1.47
		2	1.35	1.35	1.36	1.37	1.46
		3	1.41	1.38	1.37	1.33	1.31
Group V 400MPK DI		4	1.38	1.37	1.45	1.35	1.28
		5	1.46	1.46	1.49	1.43	1.24
		6	1.47	1.31	1.42	1.44	1.36
		Avg	1.42	1.39	1.4	1.4	1.35
		Stdev	0.05	0.06	0.06	0.05	0.1
	PREGABALIN 5 MPK	1	1.16	1.27	1.16	1.16	1.06
		2	1.18	1.18	1.18	1.34	1.07
Group VI PREG 5 MPK		3	1.26	1.09	1.24	1.03	1.16
		4	1.24	1.11	1.08	1.42	1.15
		5	1.14	1.06	1.12	1.08	1.28
		6	1.28	1.08	1.14	1.17	1.14
		Avg	1.21	1.13	1.15	1.2	1.14
		Stdev	0.06	0.08	0.05	0.15	0.08

SUMMARY				
Anova: Single Factor				
Groups	*Count*	*Sum*	*Average*	*Variance*
Group I Untreated Uninduced	5	0.25	0.05	0
Group II Treated Uninduced	5	0.25	0.05	0
Group III PT 2mpk	5	10.59	2.118	0.00437
Group IV 200mpk DI	5	8.97	1.794	0.00068
Group V 400MPK DI	5	6.96	1.392	0.00067
Group VI PREG 5 MPK	5	5.83	1.166	0.00133

ANOVA						
Source of Variation	*SS*	*df*	*MS*	*F*	*P-value*	*F crit*
Between Groups	19.06215	5	3.81243	3244.621	3.91E-33	2.620654

Within Groups	0.0282	24	0.001175			
Total	19.09035	29				

The IL-6 investigation surveys provocative cytokine levels over time. The untreated uninduced and treated uninduced groups keep up moo IL-6 levels, demonstrating no noteworthy provocative reaction. Within the initiated untreated gather, IL-6 levels rise strongly, reflecting dynamic aggravation. DI 200 MPK and DI 400 MPK groupsappear a noteworthy lessening in IL-6 levels, highlighting their anti-inflammatory potential. The Pregabalin 5 MPK bunch too illustrates a diminish in IL-6, in spite of the fact that somewhat less articulated compared to DI medicines. The information appears moo standard deviations, strengthening the consistency of the estimations. This examination shows that DI and Pregabalin medications decrease IL-6 levels, with DI 400 MPK being the foremost viable. These discoveries propose that the tried medications can moderate irritation through the concealment of IL-6 generation.

DISCUSSION

Over sixteen days, the Hot Plate Strategy gages withdrawal inactivity to evaluate torment affectability over numerous treatment groups. The to some degree consistent normal withdrawal delay of Bunch I (Untreated Uninduced) demonstrated no calculable alter over time. Higher withdrawal latencies appeared by Gather II (Treated Uninduced) recommended diligent torment resilience. With much diminished withdrawal delay, Gather III (Actuated Untreated) recommended humble but reliable torment resistance. DI 200 MPK to some degree progressed withdrawal inactivity with time, hence advertising a few direct torment mitigation. Higher withdrawal latencies than the lower measurement bunch demonstrated DI 400 MPK appeared tireless torment resilience. With superior withdrawal latencies, pregabalin 5 MPK proposed great torment mitigation. Gather III (Initiated Untreated) had the most prominent torment affectability; Gather II (Treated Uninduced) and Bunch V (DI 400 MPK) appeared the foremost reliable torment mitigation at final. Over the watching period, DI 400 MPK and Pregabalin 5 MPK medicines were the foremost effective in moving forward torment tolerance. The plantar test gages withdrawal idleness, subsequently deciding the torment limit and the pain relieving properties of different treatments. Comes about uncover self-evident contrasts over groups and times focuses (Day to Day 16). Whereas Bunch II (Treated Uninduced) illustrated a more prominent and steady withdrawal inactivity, appearing that the treatment impressively raised torment resistance in uninduced patients, Bunch I (Untreated Uninduced) had a to some degree relentless withdrawal idleness. With the least withdrawal latencies, Gather III (Actuated Untreated) recommended that acceptance diminishes the torment edge, hence expanding the affectability of patients to stimuli.

Recommending a minor pain relieving impact, Gather IV (DI 200 MPK) appeared a small increment in withdrawal delay relative to the activated treatment bunch. Actuating treatment and DI 200 MPK groups appeared lower withdrawal latencies than Gather V (DI 400 MPK), hence proposing a more prominent pain relieving impact at the higher dose. Among all the initiated groups, Bunch VI (Pregabalin 5 MPK) had the greatest withdrawal latencies; this proposes that pregabalin incorporates a outstanding and ceaseless pain relieving action. Tumour necrosis figure (TNF) ponder appears cytokine movement related with incendiary forms. Steady moo OD450 values within the untreated uninduced bunch point to small TNF union. Reflecting expanded TNF levels and an dynamic fiery reaction, the actuated treated gather shows a noteworthy rise in OD450 though the treated uninduced bunch holds moo values. Diminished TNF levels in DI 200 MPK and DI 400 MPK medicines compared to the actuated untreated bunch point to anti-inflammatory action. The IL-6 consider charts incendiary cytokine levels all through time. Moo IL-6 levels in both treated and untreated uninduced groups point to no calculable fiery reaction. Their anti-inflammatory activity is highlighted by noteworthy drop in IL-6 levels seen by DI 200 MPK and DI 400 MPK groups.

CONCLUSION

The study sought to use Dihydrocorticosteroids (DI) and Pregabalin to treat inflammatory pain. It found that in Group III, withdrawal latencies linked with higher pain sensitivity arising from inflammation in the

absence of therapy. While DI 400 MPK showed more powerful analgesic effects than DI 600 MPK, both DI 200 MPK and DI 400 MPK showed dose-dependent advantages. Pregabalin 5 MPK obviously provides significant and long-lasting analgesic effect based on highest pain tolerance. Although DI therapies practically reduced these cytokines, proving their anti-inflammatory and immunomodulating effects, inflammation was considerably raised by cytokines including IL-1, TNF, and IL-6. Pregabalin lowered cytokine production, less than DI 400 MPK. The most effective treatments were pregabalin 5 MPK and DI 400 MPK; pregabalin is more effective in reducing pain, whilst DI 400 MPK has the most significant anti-inflammatory impact. The results of the investigation show that the cannabidiol (CBD2) agonist has this effect, therefore indicating a considerable modulating impact on the overexpression of BNDF. Activation of the CBD2 receptor has been shown to have the ability to change the BNDF concentration, presumably by means of a neuroprotective and anti-inflammatory treatment. Our findings underline the therapeutic possibilities of cannabidiol (CBD2) agonists in diseases linked with BNDF dysregulation, including neuroprotective sickness, chronic pain, and neuroinflammatory disorder. The next paragraphs will go further on these illnesses. More study is needed to investigate the molecular mechanisms involved and to support these advantages in a clinical environment.

REFERENCE

1. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature 1993, 365, 61–65.
2. Mackie, K. Cannabinoid Receptors: Where They Are and What They Do. J. Neuroendocrinol. 2008, 20, 10–14.
3. Maccarrone, M.; Battista, N.; Centonze, D. The Endocannabinoid Pathway in Huntington's Disease: A Comparison with Other Neurodegenerative Diseases. Prog. Neurobiol. 2007, 81, 349–379.
4. Bouaboula, M.; Poinot-Chazel, C.; Marchand, J.; Canat, X.; Bourrié, B.; Rinaldi-Carmona, M.; Calandra, B.; Le Fur, G.; Casellas, P. Signaling Pathway Associated with Stimulation of CB2 Peripheral Cannabinoid Receptor. Eur. J. Biochem. 1996, 237, 704–711.
5. Soethoudt, M.; Grether, U.; Fingerle, J.; Grim, T. W.; Fezza, F.; De Petrocellis, L.; Ullmer, C.; Rothenhäusler, B.; Perret, C.; Van Gils, N., et al. Cannabinoid CB2 Receptor Ligand Profiling Reveals Biased Signalling and Off-Target Activity. Nat. Commun. 2017, 8, 13958.
6. Li, X.; Hua, T.; Vemuri, K.; Ho, J.-H.; Wu, Y.; Wu, L.; Popov, P.; Benchama, O.; Zvonok, N.; Locke, K. A., et al. Crystal Structure of the Human Cannabinoid Receptor CB2. Cell 2019, 176, 459–467.
7. Hua, T.; Li, X.; Wu, L.; Iliopoulos-Tsoutsouvas, C.; Wang, Y.; Wu, M.; Shen, L.; Johnston, C. A.; Nikas, S. P.; Song, F., et al. Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures. Cell 2020, 180, 1–11.
8. Xing, C.; Zhuang, Y.; Xu, T.-H.; Feng, Z.; Zhou, X. E.; Chen, M.; Wang, L.; Meng, X.; Xue, Y.; Wang, J., et al. Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex. Cell 2020, 180, 645–654.e13.
9. Kelsey, G.; Guenther, A.; Lin, X.; Xu, Z.; Makriyannis, A.; Romero, J.; Hillard, C. J.; Mackie, K.; Hohmann, A. G. Cannabinoid CB2 Receptors in Primary Sensory Neurons Are Implicated in CB2 Agonist-Mediated Suppression of Paclitaxel-Induced Neuropathic Nociception and Sexually-Dimorphic Sparing of Morphine Tolerance. bioRxiv 2024, DOI: 10.1101/2024.03.05.583426.
10. Borgonetti, V.; Mugnaini, C.; Corelli, F.; Galeotti, N. The Selective CB2 Agonist COR167 Reduced Symptoms in a Mice Model of Trauma-Induced Peripheral Neuropathy through HDAC-1 Inhibition. Biomedicines 2023, 11 (6), 1546. https://doi.org/10.3390/biomedicines11061546.
11. Bergen, M. The Changing Brain: The Interactive Role of Brain-Derived Neurotrophic Factor, Cannabinoids, and the Endocannabinoid System in Neurogenic and Neuroplastic Processes of the Brain. Unpublished Manuscript, 2020.
12. Burston, J. J.; et al. Cannabinoid CB2 Receptor Activation Reduces Central and Peripheral Neuropathic Pain. Pain 2013, 154 (10), 1930–1939.
13. Zhang, Y.; et al. The Role of Cannabinoid Receptor 2 in Neuropathic Pain Management. Neuropharmacology 2020, 177, 108160.
14. Huang, W. J.; et al. Emerging Molecular Targets for Neuropathic Pain Treatment. Front. Pharmacol. 2022, 13, 916200.
15. Finnerup, N. B.; et al. Pharmacotherapy for Neuropathic Pain in Adults: A Systematic Review. Lancet Neurol. 2015, 14 (2), 162–173.
16. Wang, L.; et al. Oxidative Stress and Neuroinflammation in Cisplatin-Induced Neuropathic Pain. Neurosci. Lett. 2021, 756, 135944.